Evrysdi
PTC sells royalty rights of SMA drug Evrysdi to Royalty Pharma for $1.5B
Anika Sharma
As part of its cost-cutting efforts and in response to potential challenges in the European market, PTC Therapeutics is taking ...
Roche’s Evrysdi Illuminates Hope: EC Expands Approval for SMA Infants
Anika Sharma
To provide a brighter future for infants battling spinal muscular atrophy (SMA), Roche has unveiled a momentous development. The European ...
